A phase 3b trial demonstrated that tildrakizumab, an interleukin-23 p19 inhibitor, maintained sustained efficacy and safety for moderate-to-severe scalp psoriasis at 52 weeks. Patients receiving tildrakizumab showed improved response rates; quality of life measures also demonstrated significant improvements. Adverse events occurred in 53% of tildrakizumab-treated patients and 51.8% of crossover patients, with serious adverse events reported in 2.6% and 3.5%, respectively. Common events included nasopharyngitis, headache, and hypertension. Major adverse cardiovascular events occurred in two patients per group, all with relevant medical histories.

Source: Journal of the American Academy of Dermatology